Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in healthy Japanese and Caucasian subjects
NCT02568423Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2015
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mirikizumab in ulcerative colitis (UC) and Crohn's disease (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Serious Adverse Events at 85 days. Started Dec 2015; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02568423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568423.